|
2021 Conference Publication 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603)Hofman, Michael S., Emmett, Louise, Sandhu, Shahneen Kaur, Iravani, Amir, Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Ng, Siobhan, Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Zhang, Alison Yan, McJannett, Margaret Mary, Stockler, Martin R., Violet, John A., Williams, Scott, Martin, Andrew James and Davis, Ian D. (2021). 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603). ASCO Genitourinary Cancers Symposium (GU ASCO), Online, 11-13 February 2021. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2021.39.6_suppl.6 |
|
2019 Conference Publication Combination of avelumabwith peptide receptor radionuclide therapy (PRRT) or conventional fractionated radiotherapy (RT) in metastatic merkel cell carcinoma (mMCC) [GoTHAM study]Sandhu, Shahneen, Tothill, Richard, Scolyer, Richard, Guminski, Alexander, Becker, Juergen, Poulsen, Michael, Atkinson, Victoria, Neeson, Paul, Shackleton, Mark, Pattison, David, Williams, Narelle and Paton, Elizabeth (2019). Combination of avelumabwith peptide receptor radionuclide therapy (PRRT) or conventional fractionated radiotherapy (RT) in metastatic merkel cell carcinoma (mMCC) [GoTHAM study]. COSA's 46th Annual Scientific Meeting, Urological cancer; Age and gender in cancer practice; Digital health in cancer, Adelaide, SA, Australia, 12–14 November 2019. Hoboken, NJ, United States: Wiley. |
|
2019 Conference Publication A prospective intra-individual blinded comparison of 18F-PSMA-1007 and 68GA-PSMA-11 PET/CT imaging in patients with confirmed prostate cancerDebowski, M., Gulhane, B., Ramsay, S. C., Thomas, P. A., Garcia, P., Latter, M., Tapper, S. and Pattison, D. A. (2019). A prospective intra-individual blinded comparison of 18F-PSMA-1007 and 68GA-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer. Australian and New Zealand Society of Nuclear Medicine (ANZSNM) 49th ASM, Adelaide, SA, Australia, 26–28 April 2019. Hoboken, NJ, United States: Wiley. |
|
2018 Conference Publication Targeted Molecular Imaging of Translocator Protein (TSPO) Using (18F)GE180-PET for the Diagnosis of Gastrointestinal Graft Versus host Disease (GI-GVHD)Scott, Ashleigh P., Tey, Siok-Keen, Thomas, Paul, Pattison, David and Kennedy, Glen A. (2018). Targeted Molecular Imaging of Translocator Protein (TSPO) Using (18F)GE180-PET for the Diagnosis of Gastrointestinal Graft Versus host Disease (GI-GVHD). 60th Annual Meeting of the American Society of Hematology (ASH), San Diego, CA United States, 1-4 December 2018. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2018-99-114114 |
|
2018 Conference Publication (18)FDG PET/CT CARDIAC SARCOID IMAGING: MONITORING KETONE LEVELS TO AVOID INADEQUATE SUPPRESSION OF PHYSIOLOGIC MYOCARDIAL UPTAKERobinson, B., Pattison, D. and Lee, K. (2018). (18)FDG PET/CT CARDIAC SARCOID IMAGING: MONITORING KETONE LEVELS TO AVOID INADEQUATE SUPPRESSION OF PHYSIOLOGIC MYOCARDIAL UPTAKE. HOBOKEN: WILEY. |
|
2018 Conference Publication Positron Emission Tomography (PET) predictors of tumor response to Peptide Receptor Radionuclide Therapy (PRRT) in metastatic Neuroendocrine Tumors (NET)Ladwa, R., Pattison, D., Smith, J., Goodman, S., Burge, M., Rose, S., Dowson, N. and Wyld, D. (2018). Positron Emission Tomography (PET) predictors of tumor response to Peptide Receptor Radionuclide Therapy (PRRT) in metastatic Neuroendocrine Tumors (NET). 15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, 7-9 March 2018. Basel, Switzerland: S. Karger AG. |
|
2018 Conference Publication Tumor absorbed dosimetry and response of radionuclide therapy in metastatic neuroendocrine tumorLadwa, R., Pattison, D., Smith, J., Goodman, S., Burge, M., Rose, S., Dowson, N. and Wyld, D. (2018). Tumor absorbed dosimetry and response of radionuclide therapy in metastatic neuroendocrine tumor. 15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, 7-9 March 2018. Basel, Switzerland: S. Karger AG. |
|
2018 Conference Publication Validation of Abbreviated 177Lu-DOTATATE Renal and Lesional Dosimetry Protocol using Quantitative SPECTGoodman, Steven , Patford, Shaun , Ladwa, Rahul , Smith, Jye , Wyld, David and Pattison, David A. (2018). Validation of Abbreviated 177Lu-DOTATATE Renal and Lesional Dosimetry Protocol using Quantitative SPECT. 12th Congress of the World Federation of Nuclear Medicine and Biology., Melbourne Australia, 20-24 April 2018. |
|
2018 Conference Publication Pretherapeutic predictors of tumor absorbed dosimetry in radionuclide therapy for metastatic neuroendocrine tumorsLadwa, R., Pattison, D., Smith, J., Goodman, S., Burg, M., Rose, S., Dowson, N. and Wyld, D. (2018). Pretherapeutic predictors of tumor absorbed dosimetry in radionuclide therapy for metastatic neuroendocrine tumors. 15th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, 7-9 March 2018. Basel, Switzerland: S. Karger AG. |
|
2017 Conference Publication 177Lu-DOTA-OCTREOTATE PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) IN PATIENTS WITH FUNCTIONAL AND METASTATIC PHAEOCHROMOCYTOMA (PCC) OR PARAGANGLIOMA (PGL)Kong, G., Grozinsky-Glasberg, S., Callahan, J., Hofman, M. S., Meirovitz, A., Maimon, O., Pattison, D. A., Gross, D. J. and Hicks, R. J. (2017). 177Lu-DOTA-OCTREOTATE PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRT) IN PATIENTS WITH FUNCTIONAL AND METASTATIC PHAEOCHROMOCYTOMA (PCC) OR PARAGANGLIOMA (PGL). HOBOKEN: WILEY. |
|
2017 Conference Publication USING A FORMULA BASED ON BMI AND BSL FOR ADMINISTRATION OF ACTRAPID FOR FDG-PET SCANS WHERE THE PATIENT'S BSL IS ELEVATED ON ARRIVALMacFarlane, L. and Pattison, D. (2017). USING A FORMULA BASED ON BMI AND BSL FOR ADMINISTRATION OF ACTRAPID FOR FDG-PET SCANS WHERE THE PATIENT'S BSL IS ELEVATED ON ARRIVAL. HOBOKEN: WILEY. |
|
2017 Conference Publication Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Functional and Metastatic Phaeochromocytoma (PCC) and Paraganglioma (PGL)Kong, G., Grozinsky-Glasberg, S., Callahan, J., Hofman, M., Meirovitz, A., Maimon, O., Pattison, D., Gross, D. and Hicks, R. (2017). Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Functional and Metastatic Phaeochromocytoma (PCC) and Paraganglioma (PGL). 14th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona Spain, Mar 08-10, 2017. BASEL: KARGER. |
|
2017 Conference Publication The management of refractory catecholamine associated symptoms in malignant phaeochromocytomaMossman, Anna, Pattison, David, Inchley, Fiona and Hamblin, P. Shane (2017). The management of refractory catecholamine associated symptoms in malignant phaeochromocytoma. HOBOKEN: WILEY-BLACKWELL. |
|
2016 Conference Publication HIGH EFFICACY FROM A PERSONALISED APPROACH USING Y-90-DOTA-OCTREOTATE SEQUENCED WITH (LU)-L-177-DOTA-OCTREOTATE INDUCTION PEPTIDE RECEPTOR CHEMORADIONUCLIDE THERAPY (PRCRT) FOR BULKY NEUROENDOCRINE TUMOURSKong, G., Callahan, J., Hofman, M., Pattison, D., Akhurst, T., Michael, M., Eu, P. and Hicks, R. (2016). HIGH EFFICACY FROM A PERSONALISED APPROACH USING Y-90-DOTA-OCTREOTATE SEQUENCED WITH (LU)-L-177-DOTA-OCTREOTATE INDUCTION PEPTIDE RECEPTOR CHEMORADIONUCLIDE THERAPY (PRCRT) FOR BULKY NEUROENDOCRINE TUMOURS. HOBOKEN: WILEY-BLACKWELL. |
|
2016 Conference Publication PRELIMINARY RESULTS OF (68)GA EXENDIN-4 PET/CT IMAGING OF NEUROENDOCRINE TUMOURS (NETS)Pattison, D., Kong, G., Messazos, B., Hamblin, P., Fourlanos, S., Lee, M., Michael, M., Hong, E., Eu, P. and Hicks, R. (2016). PRELIMINARY RESULTS OF (68)GA EXENDIN-4 PET/CT IMAGING OF NEUROENDOCRINE TUMOURS (NETS). HOBOKEN: WILEY-BLACKWELL. |
|
2016 Conference Publication Favourable responses in Patients with Bulky Neuroendocrine Tumours (NET) A Personalised Approach Using 90Y-DOTA-Octreotate Sequenced with 177Lu-DOTA-Octreotate Induction Peptide Receptor Chemoradionuclide Therapy (PRCRT)Kong, G., Callahan, J., Hofman, M., Pattison, D., Akhurst, T., Michael, M., Eu, P. and Hicks, R. (2016). Favourable responses in Patients with Bulky Neuroendocrine Tumours (NET) A Personalised Approach Using 90Y-DOTA-Octreotate Sequenced with 177Lu-DOTA-Octreotate Induction Peptide Receptor Chemoradionuclide Therapy (PRCRT). 13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona Spain, Mar 09-11, 2016. BASEL: KARGER. |
|
2015 Conference Publication MANAGEMENT OF HYPERTENSIVE CRISIS IN PARAGANGLIOMA-A CASE REPORTJackson, Cheryl, Lingaratnam, Senthil, Michael, Michael and Pattison, David (2015). MANAGEMENT OF HYPERTENSIVE CRISIS IN PARAGANGLIOMA-A CASE REPORT. HOBOKEN: WILEY-BLACKWELL. |
|
2015 Conference Publication GA-68 DOTA-OCTREOTATE (GATATE) AND F-18 FLUORODEOXYGLUCOSE (FDG) PET/CT IN THE ASSESSMENT OF PARAGANGLIOMAS AND PHEOCHROMOCYTOMASChang, C. A., Hofman, M., Thompson, M., Pattison, D. and Hicks, R. (2015). GA-68 DOTA-OCTREOTATE (GATATE) AND F-18 FLUORODEOXYGLUCOSE (FDG) PET/CT IN THE ASSESSMENT OF PARAGANGLIOMAS AND PHEOCHROMOCYTOMAS. HOBOKEN: WILEY-BLACKWELL. |
|
2015 Conference Publication IMPROVED SURVIVAL OF POOR PROGNOSIS FDG-AVID NEUROENDOCRINE TUMOURS WITH LU-177 OCTREOTATE PEPTIDE RECEPTOR CHEMORADIONUCLIDE THERAPY (PRCRT)Hofman, M. S., Kashyap, R., Kong, G., Akhurst, T., Pattison, D., Eu, P. and Hicks, R. J. (2015). IMPROVED SURVIVAL OF POOR PROGNOSIS FDG-AVID NEUROENDOCRINE TUMOURS WITH LU-177 OCTREOTATE PEPTIDE RECEPTOR CHEMORADIONUCLIDE THERAPY (PRCRT). HOBOKEN: WILEY-BLACKWELL. |
|
2014 Conference Publication STONES, GROANS AND BONESCrowther, M. and Pattison, D. (2014). STONES, GROANS AND BONES. HOBOKEN: WILEY-BLACKWELL. |
